Soluble forms of many malaria vaccine candidates AMA1, MSP1 and Pfs25 in human-use adjuvants have thus far failed to induce protective immune response but when formulated in highly reactive adjuvants such as Freunds Complete and Montanide, potent anti-malarial responses have been reported [52–56]. The gene discussed is ATAD1; the disease is malaria.